The purpose of the ILCA Guidances is to broaden awareness and deepen knowledge about recent, relevant research diagnosis and treatment of liver cancer. Expand ILCA’s thought leadership through generating additional guidance documentation offering an invaluable resource in the correct management of liver cancer.
Transarterial Chemoembolisation (TACE) Consensus Guidance
A multi-disciplinary working group of oncologists, surgeons, hepatologists and scientists is working together to draft clinical questions and literature search for this manuscript. More details and information will be published by the end of 2021.
Biomarker Development for Hepatocellular Carcinoma
There is an urgent clinical need for new biomarkers in hepatocellular carcinoma, including better tools for early tumor detection and prediction of response to systemic therapies.
The International Liver Cancer Association has put together an exceptional team of experts led by Drs. Villanueva and Singal, who recently published a white paper with recommendations on the design, interpretation and reporting of biomarker studies in hepatocellular carcinoma. This addresses the much needed guidance for academia and industry on the best approach to develop new biomarkers for this devastating disease.
ILCA Systemic Therapy Guidance
- Interactive therapeutic algorithm
- Summary of and links to key data that provide the evidence base for current therapy
- Focussed discussion on clinical decision making according to specific clinical contexts